Stock listing
Shenzhen:301569 Novast Laboratories Ltd (联亚药业) 股价
Follow Novast Laboratories Ltd into a list and get an email when it puts out news.
Share price · SZSE:301569
¥15.01 CNY -0.99 (-6.2%)
Close on Nov 20, 2026
- Day range
- ¥15.01 – ¥15.87 CNYNov 20, 2026
- Volume
- 14.54M sharesNov 20, 2026
- Market cap
- ¥13.38B CNYAt the close on Nov 20, 2026 · price × 891.6M shares outstanding
- Traded on an average day
- ¥882.6M CNYMedian day 40.28M shares · last 3 months, Oct 15, 2026 – Nov 20, 2026
Daily closes
Last 3 months, Oct 15, 2026 – Nov 20, 2026 · SZSE:301569 · CNY, adjusted for splits
| Day | Close | Change | % | Open | High | Low | Volume |
|---|---|---|---|---|---|---|---|
| ¥15.01 | -0.99 | -6.2% | ¥15.50 | ¥15.87 | ¥15.01 | 14,544,954 | |
| ¥16.00 | -0.73 | -4.4% | ¥16.80 | ¥16.80 | ¥15.66 | 19,797,353 | |
| ¥16.73 | -0.51 | -3.0% | ¥17.04 | ¥17.33 | ¥16.60 | 17,433,144 | |
| ¥17.24 | -0.75 | -4.2% | ¥17.76 | ¥18.00 | ¥17.17 | 17,079,542 | |
| ¥17.99 | -1.61 | -8.2% | ¥19.00 | ¥19.40 | ¥17.77 | 32,805,263 | |
| ¥19.60 | +0.34 | +1.8% | ¥19.06 | ¥19.79 | ¥19.06 | 33,536,992 | |
| ¥19.26 | -0.34 | -1.7% | ¥19.00 | ¥19.37 | ¥18.66 | 32,785,398 | |
| ¥19.60 | +0.77 | +4.1% | ¥19.16 | ¥20.27 | ¥19.16 | 34,708,316 | |
| ¥18.83 | -0.44 | -2.3% | ¥19.00 | ¥19.65 | ¥18.62 | 30,981,650 | |
| ¥19.27 | -2.52 | -11.6% | ¥20.25 | ¥21.10 | ¥19.19 | 43,187,931 | |
| ¥21.79 | +0.68 | +3.2% | ¥20.50 | ¥22.03 | ¥20.11 | 55,426,398 | |
| ¥21.11 | +1.51 | +7.7% | ¥19.62 | ¥23.51 | ¥19.62 | 58,244,887 | |
| ¥19.60 | +0.32 | +1.7% | ¥18.85 | ¥19.68 | ¥18.41 | 41,124,676 | |
| ¥19.28 | +1.06 | +5.8% | ¥18.54 | ¥19.35 | ¥17.60 | 39,431,816 | |
| ¥18.22 | +0.44 | +2.5% | ¥17.48 | ¥19.45 | ¥17.48 | 43,387,141 | |
| ¥17.78 | -1.20 | -6.3% | ¥18.65 | ¥19.48 | ¥17.50 | 33,296,027 | |
| ¥18.98 | +1.04 | +5.8% | ¥17.90 | ¥19.38 | ¥17.39 | 38,969,895 | |
| ¥17.94 | -0.95 | -5.0% | ¥18.61 | ¥18.89 | ¥17.83 | 35,316,570 | |
| ¥18.89 | +0.47 | +2.6% | ¥17.69 | ¥19.58 | ¥17.53 | 44,833,598 | |
| ¥18.42 | +0.92 | +5.3% | ¥16.98 | ¥18.74 | ¥16.75 | 48,733,816 | |
| ¥17.50 | -2.56 | -12.8% | ¥19.19 | ¥19.46 | ¥17.50 | 47,944,281 | |
| ¥20.06 | -2.03 | -9.2% | ¥21.01 | ¥22.59 | ¥20.02 | 52,069,328 | |
| ¥22.09 | +0.02 | +0.1% | ¥22.45 | ¥23.76 | ¥22.00 | 48,601,734 | |
| ¥22.07 | -3.10 | -12.3% | ¥23.88 | ¥25.90 | ¥21.90 | 57,868,695 | |
| ¥25.17 | -9.95 | -28.3% | ¥32.00 | ¥36.00 | ¥25.00 | 73,074,492 | |
| ¥35.12 | — | — | ¥27.00 | ¥42.15 | ¥27.00 | 93,230,797 |
- Ticker
- Shenzhen:301569
- Asset type
- Stock
- Sector
- Health care
- Industry
- Pharmaceuticals
- Exchange
- Shenzhen
- Currency
- CNY
Novast Laboratories Ltd on 6ix
- Sector
- Health care
- Industry
- Pharmaceuticals
Valuation
P/E 43.0× against a median of 20.5×: 9th lowest of 10 Pharmaceuticals companies shown. Statements: 4 quarters to Sep 30, 2026 · price Nov 20, 2026
- Enterprise value
- ¥11.97B CNY
- P/E
- 43.0×
- EV/sales
- 11.9×
- EV/EBITDA
- No depreciation figure on 6ix yet
- Price/book
- 5.9×
- Gross margin
- 60.3%
- Operating margin
- 37.3%
- Net margin
- 30.8%
- Debt to equity
- 0.0×
- Beta
- No index for this market yet
Pharmaceuticals: the 10 companies nearest in size, of 492 on 6ix with figures. Size in US dollars.
| Company | Mkt cap | EV | P/E | EV/Sales | EV/EBITDA | P/B | Net mgn | Debt/Eq | Beta |
|---|---|---|---|---|---|---|---|---|---|
| Novast Laboratories Ltd · SZSE:301569 | US$2.01B | US$1.80B | 43.0× | 11.9× | n/a | 5.9× | 30.8% | 0.0× | n/a |
| Alembic Pharmaceuticals Limited · NSE:APLLTD | US$2.21B | US$2.34B | 24.3× | 2.6× | 15.3× | 3.4× | 10.0% | 0.3× | n/a |
| Hebei Changshan Biochemical Pharmaceutical Co., Ltd. Class A · SZSE:300255 | US$2.18B | US$2.27B | n/a | 16.3× | n/a | 12.5× | −37.7% | 0.6× | n/a |
| Zhejiang Hisun Pharmaceutical Co., Ltd. Class A · SSE:600267 | US$2.15B | US$1.97B | 11.7× | 1.4× | n/a | 1.5× | 13.4% | 0.0× | n/a |
| Henan Lingrui Pharmaceutial Co., Ltd. Class A · SSE:600285 | US$2.04B | US$1.89B | 16.4× | 3.2× | n/a | 3.9× | 20.9% | 0.0× | n/a |
| Aurinia Pharmaceuticals Inc · NASDAQ:AUPH | US$1.97B | US$1.92B | 6.3× | 6.0× | n/a | 3.0× | 97.7% | 0.0× | 0.64 |
| Harmony Biosciences Holdings, Inc. · NASDAQ:HRMY | US$1.91B | US$1.29B | 10.7× | 1.3× | 5.4× | 1.8× | 18.1% | 0.1× | 0.57 |
| Alivus Life Sciences Ltd · NSE:ALIVUS | US$1.90B | US$1.80B | 26.3× | 6.2× | 18.1× | 4.9× | 24.9% | 0.0× | n/a |
| Pfizer Limited · NSE:PFIZER | US$1.90B | US$1.24B | 20.5× | 4.3× | 11.8× | 4.0× | 32.4% | 0.0× | n/a |
| Nanjing King-friend Biochemical Pharmaceutical Co., Ltd. Class A · SSE:603707 | US$1.90B | US$1.52B | 29.8× | 2.5× | n/a | 1.8× | 10.4% | 0.0× | n/a |
| Shenzhen Kangtai Biological Products Co. Ltd. Class A · SZSE:300601 | US$1.80B | US$1.74B | 103× | 4.7× | n/a | 1.2× | 4.8% | 0.2× | n/a |
| Median of the others | US$1.94B | US$1.84B | 20.5× | 3.8× | 13.6× | 3.2× | 15.7% | 0.0× | 0.61 |
Financials
Annual, in CNY
Income statement
| Line | FY2025 | FY2024 | FY2023 | FY2022 |
|---|---|---|---|---|
| Revenue | 895.5M | 866.2M | 700.4M | 550.1M |
| Cost of revenue | 396.4M | 394.2M | 348.9M | 270.4M |
| Gross profit | 499.0M | 472.0M | 351.5M | 279.7M |
| Research and development | 101.0M | 101.7M | 88.7M | 102.9M |
| Selling, general and administrative | 167.5M | 280.0M | 447.6M | 198.2M |
| Operating income | 267.7M | 257.5M | 120.7M | 48.7M |
| Depreciation and amortization | 35.9M | 34.6M | 34.5M | 32.7M |
| EBITDA | 303.6M | 292.1M | 155.2M | 81.4M |
| Income before tax | 263.1M | 290.1M | 136.1M | 130.2M |
| Net income | 227.8M | 260.1M | 115.8M | 113.0M |
| Earnings per share, basic | 0.30 | 0.34 | 0.15 | 0.15 |
Balance sheet
| Line | FY2025 | FY2024 | FY2023 | FY2022 |
|---|---|---|---|---|
| Cash and equivalents | 1.10B | 863.1M | 638.1M | 475.6M |
| Short-term investments | 100.2M | 146.2M | 170.4M | 228.1M |
| Receivables | 173.0M | 132.1M | 113.0M | 80.0M |
| Inventory | 214.6M | 228.0M | 262.0M | 262.6M |
| Current assets | 1.62B | 1.41B | 1.23B | 1.10B |
| Total assets | 2.29B | 2.05B | 1.75B | 1.53B |
| Accounts payable | 13.0M | 8.93M | 9.18M | 3.09M |
| Current liabilities | 166.6M | 162.8M | 112.0M | 83.6M |
| Total liabilities | 283.9M | 261.4M | 225.9M | 200.9M |
| Shareholders' equity | 2.01B | 1.79B | 1.53B | 1.33B |
| Shares outstanding | 757.9M | 757.9M | 757.9M | 757.9M |
Cash flow
| Line | FY2025 | FY2024 | FY2023 | FY2022 |
|---|---|---|---|---|
| Cash from operations | 322.6M | 267.0M | 200.9M | 209.2M |
| Capital spending | -75.3M | -105.9M | -127.0M | -69.8M |
| Free cash flow | 247.3M | 161.2M | 74.0M | 139.4M |
| Dividends paid | -68.0M | |||
| Change in cash | -10.6M | 60.5M | -104.7K | -16.7M |
Cap table
Built by 6ix from Novast Laboratories Ltd’s releases
- Common shares
- 891,597,091
- Fully diluted
- 891,597,091
Fully diluted
| Line | Shares |
|---|---|
| Common shares | 891,597,091 |
Share count over time
| Count | Shares |
|---|---|
| Nov 22, 2026 | 891,597,091 |
Log in to ask 6ix AI your own questions about Novast Laboratories Ltd.